<DOC>
	<DOCNO>NCT01655719</DOCNO>
	<brief_summary>Through trial investigator hope learn drug , Actos ( pioglitazone ) , useful treat certain kind metastatic thyroid cancer . Actos approve FDA treat diabetes . It approve FDA treat cancer , use study consider experimental .</brief_summary>
	<brief_title>Pioglitazone Thyroid Cancers</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Patients must histologically confirm thyroid carcinoma PAX8PPARgamma translocation ( translocation test perform archived tissue screen period ) . Refractory radioactive iodine ( RAI ) define : tumor concentrate RAI ; patient RAI within last 16 month progression despite RAI ; last RAI treatment &gt; 16 month ago patient progress least two RAI treatment ; patient receive RAI treatment cumulative RAI dose â‰¥22.2 GBq ( 600 mCi ) Not candidate surgery RAI therapy curative intent . Lesions would treat external beam radiation therapy ( EBRT ) base standard care treat , use target lesion . 2 . Measurable disease RECIST 1.1 criterion . 3 . Documented disease progression RECIST 1.1 past 14 month . 4 . Availability histological material ( primary tumor metastasis ) review diagnosis demonstration PAX8PPARgamma fusion gene . 5 . Adequate TSH suppression ( &lt; 0.5 mIU/L ) 6 . Prior chemotherapy surgery must complete least 28 day prior registration , toxicity must resolve . 7 . Prior radioactive iodine must complete least 6 month prior registration , must document disease progression since therapy within 6 month . Sites received EBRT must disease progression postEBRT use site measurable disease . 8 . Age 18 75 year age 9 . Life expectancy great 6 month . 10 . ECOG performance status 2 less . 11 . Patients must normal organ function define : AST ( SGOT ) /ALT ( SGPT ) less 2.5 X institutional upper limit normal ( within 1 month study Day 1 ) 12 . Patients must able consume oral medication . 13 . Women childbearing potential must negative pregnancy test baseline prior receive study drug must practice effective contraception study . ( Pregnant lactating patient exclude ) . 14 . All patient must sign informed consent prior enrollment . 1 . Patients may receive investigational agent . 2 . Patients know untreated brain metastasis . 3 . History allergic reaction attribute compound similar chemical biologic composition pioglitazone . 4 . Diagnosis diabetes mellitus current therapy drug use treat diabetes mellitus , include limited insulin , sulfonylurea , metformin , rosiglitazone ( Avandia ) , pioglitazone ( Actos ) within 14 day study Day 1 5 . Therapy rosiglitazone ( Avandia ) pioglitazone ( Actos ) time since diagnosis thyroid cancer . 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection , congestive heart failure , unstable angina pectoris , cardiac arrhythmia . 7 . Pregnant woman exclude study pioglitazone U.S. Food Drug Administration Pregnancy Category C drug . Because unknown potential risk adverse event nurse infant secondary treatment mother pioglitazone , breastfeed discontinue mother treated pioglitazone . 8 . No concurrent radiotherapy chemotherapy may give patient administration study drug . 9 . Patients uncontrolled malabsorption syndrome . 10 . Patients history congestive heart failure New York Heart Association class . 11 . Any medical psychiatric illness , opinion principal investigator , would compromise patient 's ability tolerate treatment regimen . 12 . Use rifampin ( strong CYP2C8 inducer ) within 14 day study Day 1 . 13 . Other current malignancy disease study . 14 . Grade 2 bad edema within 14 day study Day 1 , per CTCAE v4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>